Spots Global Cancer Trial Database for The Tracking Molecular Evolution for NSCLC (T-MENC) Study
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: The Tracking Molecular Evolution for NSCLC (T-MENC) Study
Official Title: Tracking Genomic Cancer Evolution in Patients for Stage IB,II and IIIA Non-small Cell Lung Cancer After Radical Resection: The Tracking Molecular Evolution for NSCLC (T-MENC) Study
Study ID: NCT03838588
Interventions
Study Description
Brief Summary: Tumor genomic clonal evolution assessed with liquid biopsy of stage IB,II and IIIA non-small cell lung cancer patients after getting radical resection. Plasma circulating tumor DNA (ctDNA) analysis detects molecule residual disease and predicts recurrence in patients. The concordance of the relative abundance of mutations in plasma ctDNA with cancer recurrence.
Detailed Description: In the study, 200 of stage IB,II and IIIA non-small cell lung cancer patients obtained radical resection will be recruited. All the patients will receive biopsy genotype assay and ctDNA liquid biopsy. The abundance of mutations of ctDNA was tracked at 4 time points, including: 1. st: 10 Days after patients received radical resection. 2. nd: When patients finished the chemotherapy or target drug delivery two cycles. 3. rd: 10 Days after patients finished the chemotherapy or target drug delivery four cycles. 4. th: When tumor recrudescence / 2 years after radical resection. Tumor genomic clonal evolution was assessed by analyzing the relative abundance of mutations in plasma circulating tumor DNA (ctDNA).
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Beijing Hospital, Beijing, Beijing, China
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
China-Japan Friendship Hospital, Beijing, Beijing, China
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
Xuanwu Hospital Capital Medical University, Beijing, Beijing, China
Beijing Chest Hospital, Capital Medical University, Beijing, Beijing, China
Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Hebei General Hospital, Shijiazhuang, Hebei, China
Tangshan People's Hospital, Tangshan, Hebei, China
The First Bethune Hospital of Jilin University, Changchun, Jilin, China
Contact Details
Name: Yi Zhang, MD
Affiliation: Xuanwu Hospital, Beijing
Role: STUDY_CHAIR
Name: Yao guang Sun, MD
Affiliation: Beijing Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Jie Li, MD
Affiliation: Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China +86-139 1189 2587 lijie821cn@163.com
Role: PRINCIPAL_INVESTIGATOR
Name: Hong Zhang, MD
Affiliation: The First Hospital of Jilin University
Role: PRINCIPAL_INVESTIGATOR
Name: Zhi qiang Wang, MD
Affiliation: Tangshan People's Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Ming He, MD
Affiliation: Beijing Chest Hospital, Capital Medical University
Role: PRINCIPAL_INVESTIGATOR
Name: Zi dan Wang, MD
Affiliation: Beijing Chest Hospital, Capital Medical University
Role: PRINCIPAL_INVESTIGATOR
Name: Li jun Liu, MD
Affiliation: Hebei General Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Kang Shao, MD
Affiliation: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Role: PRINCIPAL_INVESTIGATOR
Name: Chao yang Liang
Affiliation: China-Japan Friendship Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
